Akebia Therapeutics (STU:AX9) Scaled Net Operating Assets : -0.11 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Akebia Therapeutics's operating assets for the quarter that ended in Mar. 2024 was €168.8 Mil. Akebia Therapeutics's operating liabilities for the quarter that ended in Mar. 2024 was €193.1 Mil. Akebia Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was €221.6 Mil. Therefore, Akebia Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.11.

Akebia Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Akebia Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Scaled Net Operating Assets Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.37

0.13

0.10

0.03

-0.07

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.03	-0.08	-0.11	-0.11	-0.11

Competitive Comparison of Akebia Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Akebia Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Scaled Net Operating Assets falls into.

Akebia Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Akebia Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(182.28	-	205.56)	/	336.115
=	-0.07

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	221.642	-	39.362
=	182.28

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	249.687	-	23.961	-	20.166
=	205.56

Akebia Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(168.835	-	193.092)	/	221.642
=	-0.11

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	207.439	-	38.604
=	168.835

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	232.516	-	34.759	-	4.665
=	193.092

Akebia Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (STU:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

AKBA:USA AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines